Scott Antonia, MD, PhD

Charles B. Simone, II, MD

FDA’s New Acting Commissioner

Howard (Jack) West, MD

Lorlatinib’s Role in ROS1-Positive Lung Cancer

PACIFIC Flooded Us with Optimism. Now What?

NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During Social Media Event

ICU Care for the Patient with Lung Cancer

Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients with Advanced NSCLC

Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer

Financial Incentives and Free Treatment Aids for Smoking Cessation in the Workplace

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung Cancer